5,585 reports of this reaction
4.0% of all DROSPIRENONE AND ETHINYL ESTRADIOL reports
#7 most reported adverse reaction
CHOLECYSTITIS CHRONIC is the #7 most commonly reported adverse reaction for DROSPIRENONE AND ETHINYL ESTRADIOL, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 5,585 FDA adverse event reports linking DROSPIRENONE AND ETHINYL ESTRADIOL to CHOLECYSTITIS CHRONIC. This represents approximately 4.0% of all 140,358 adverse event reports for this drug.
Patients taking DROSPIRENONE AND ETHINYL ESTRADIOL who experience cholecystitis chronic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHOLECYSTITIS CHRONIC is moderately reported among DROSPIRENONE AND ETHINYL ESTRADIOL users, representing a notable but not dominant share of adverse events.
In addition to cholecystitis chronic, the following adverse reactions have been reported for DROSPIRENONE AND ETHINYL ESTRADIOL:
CHOLECYSTITIS CHRONIC has been reported as an adverse event in 5,585 FDA reports for DROSPIRENONE AND ETHINYL ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHOLECYSTITIS CHRONIC accounts for approximately 4.0% of all adverse event reports for DROSPIRENONE AND ETHINYL ESTRADIOL, making it a notable side effect.
If you experience cholecystitis chronic while taking DROSPIRENONE AND ETHINYL ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.